The rapid adaptation of SARS-CoV-2-rise of the variants: transmission and resistance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Soh, Sandrine M. | - |
dc.contributor.author | Kim, Yeongjun | - |
dc.contributor.author | Kim, Chanwoo | - |
dc.contributor.author | Jang, Ui Soon | - |
dc.contributor.author | Lee, Hye-Ra | - |
dc.date.accessioned | 2022-02-24T11:40:22Z | - |
dc.date.available | 2022-02-24T11:40:22Z | - |
dc.date.created | 2022-02-07 | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 1225-8873 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/136734 | - |
dc.description.abstract | The causative factor of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously mutating. Interestingly, identified mutations mainly occur in the spike (S) protein which interacts with the ACE2 receptor and is cleaved via serine protease TMPRSS2. Some mutated strains are becoming dominant in various parts of the globe because of increased transmissibility as well as cell entry efficacy. Remarkably, the neutralizing activity of monoclonal antibodies, convalescent sera, and vaccines against the variants has been reported to be significantly reduced. Therefore, the efficacy of various monoclonal antibodies therapy and vaccines against these variants is becoming a great global concern. We herein summarize the current status of SARS-CoV-2 with gears shifted towards the recent and most common genetic variants in relation to transmission, neutralizing activity, and vaccine efficacy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MICROBIOLOGICAL SOCIETY KOREA | - |
dc.subject | RESPIRATORY SYNDROME CORONAVIRUS | - |
dc.subject | NEUTRALIZING ANTIBODIES | - |
dc.subject | VACCINE | - |
dc.subject | MUTATIONS | - |
dc.subject | COVID-19 | - |
dc.subject | REPLICATION | - |
dc.subject | B.1.1.7 | - |
dc.subject | DOMAIN | - |
dc.subject | CELL | - |
dc.subject | P.1 | - |
dc.title | The rapid adaptation of SARS-CoV-2-rise of the variants: transmission and resistance | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yeongjun | - |
dc.contributor.affiliatedAuthor | Lee, Hye-Ra | - |
dc.identifier.doi | 10.1007/s12275-021-1348-5 | - |
dc.identifier.scopusid | 2-s2.0-85113452891 | - |
dc.identifier.wosid | 000690948500001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF MICROBIOLOGY, v.59, no.9, pp.807 - 818 | - |
dc.relation.isPartOf | JOURNAL OF MICROBIOLOGY | - |
dc.citation.title | JOURNAL OF MICROBIOLOGY | - |
dc.citation.volume | 59 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 807 | - |
dc.citation.endPage | 818 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002748612 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.subject.keywordPlus | B.1.1.7 | - |
dc.subject.keywordPlus | CELL | - |
dc.subject.keywordPlus | COVID-19 | - |
dc.subject.keywordPlus | DOMAIN | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | NEUTRALIZING ANTIBODIES | - |
dc.subject.keywordPlus | P.1 | - |
dc.subject.keywordPlus | REPLICATION | - |
dc.subject.keywordPlus | RESPIRATORY SYNDROME CORONAVIRUS | - |
dc.subject.keywordPlus | VACCINE | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | monoclonal antibodies | - |
dc.subject.keywordAuthor | neutralization | - |
dc.subject.keywordAuthor | transmission | - |
dc.subject.keywordAuthor | vaccine | - |
dc.subject.keywordAuthor | variants | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.